Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 8/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | MST1R | Q04912 | 1/20 | 0.33 |
| ▸ | INPPL1 | O15357 | 7/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.30 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17661856 | 0.86 | MET (0.31) | MET | |
| SCHEMBL22905071 | 0.83 | PDE2A (0.34) | METSRCKDRKITFGFR2 | |
| SCHEMBL29443097 | 0.83 | PDE2A (0.34) | METSRCKDRKITFGFR2 | |
| SCHEMBL12263315 | 0.82 | MET (0.33) | METSRCKDRKITFGFR2 | |
| SCHEMBL12325037 | 0.82 | MET (0.45) | METSRCKDRKITFGFR2 | |
| SCHEMBL11890580 | 0.80 | CES2 (0.32) | — | |
| SCHEMBL14647720 | 0.80 | MET (0.35) | METSRCKDRKITFGFR2 | |
| SCHEMBL12360639 | 0.80 | HTR2A (0.37) | — | |
| SCHEMBL3873608 | 0.78 | MET (0.34) | METINPPL1TSHR | |
| SCHEMBL13748259 | 0.75 | HTR2A (0.39) | METSMN1; SMN2KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399299-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | AMYGDALA NEUROSCIENCES, INC. (US) | 2023-12-14 | — | — | US | disclosed |
| US-20210220376-A1 | ADDICTION TREATMENT OF AN ALCOHOL-CONSUMING PATIENT POPULATION | AMYGDALA NEUROSCIENCES, INC. (US) | 2021-07-22 | — | — | US | disclosed |
| US-20200237789-A1 | COMBINATION THERAPY FOR PREVENTING ADDICTION | AMYGDALA NEUROSCIENCES, INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-9987295-B2 | Compounds for the treatment of addiction | AMYGDALA NEUROSCIENCES, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170266210-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-9610299-B2 | Compounds for the treatment of addiction | GILEAD SCIENCES, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9610299-B2 | Compounds for the treatment of addiction | GILEAD SCIENCES, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20150250805-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2015-09-10 | — | — | US | disclosed |
| US-9000015-B2 | Compounds for the treatment of addiction | GILEAD SCIENCES, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8835423-B2 | Azepine inhibitors of janus kinases | INCYTE CORPORATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-8575353-B2 | Compounds for the treatment of addiction | GILEAD SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8563541-B2 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| US-8558001-B2 | Compounds for the treatment of addiction | GILEAD SCIENCES, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130203704-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130005689-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | GILEAD SCIENCES, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005689-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | GILEAD SCIENCES, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-20120329782-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION (US) | 2012-12-27 | — | — | US | disclosed |
| US-20090197869-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION, A DELAWARE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329782-A1 | AZEPINE INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | MET 1571/4885SRC 161/4885KDR 1244/4885 |
| US-20130203704-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | OPRK1, OPRM1, OPRD1 | MET 772/4885SRC 1320/4885KDR 4319/4885 |
| US-20200237789-A1 | COMBINATION THERAPY FOR PREVENTING ADDICTION | ALDH2, ALDH1A1, ALDH3A1 | MET 773/4885SRC 4613/4885KDR 2772/4885 |
| US-20150250805-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | OPRK1, OPRM1, OPRD1 | MET 772/4885SRC 1320/4885KDR 4319/4885 |
| US-20130005689-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | OPRK1, OPRM1, OPRD1 | MET 772/4885SRC 1320/4885KDR 4319/4885 |
| US-20210220376-A1 | ADDICTION TREATMENT OF AN ALCOHOL-CONSUMING PATIENT POPULATION | ADH1A, ADH1C, ALDH1A1 | MET 1073/4885SRC 4697/4885KDR 3223/4885 |
| US-20170266210-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | OPRK1, OPRM1, OPRD1 | MET 772/4885SRC 1320/4885KDR 4319/4885 |
| US-20230399299-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | ALDH1A1, ALDH2, ALDH3A1 | MET 1651/4885SRC 3967/4885KDR 2180/4885 |
| US-20090197869-A1 | AZEPINE INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | MET 1571/4885SRC 161/4885KDR 1244/4885 |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | JAK1, JAK3, JAK2 | MET 1571/4885SRC 161/4885KDR 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.